Article
KRAS mutation screening by chip-based DNA hybridization--a further step towards personalized oncology.
The Analyst - 21 Apr 2015
Steinbach Christine, Steinbrücker Carolin, Pollok Sibyll, Walther Katharina, Clement Joachim H, Chen Yuan, Petersen Iver, Cialla-May Dana, Weber Karina, Popp Jürgen
Abstract excerpt
The use of predictive biomarkers can help to improve therapeutic options for the individual cancer patient. For the treatment of colon cancer patients with anti-EGFR-based drugs, the KRAS mutation status has to be determined to pre-select responders that will benefit from this medication. Amongst others, array-based tests have been established for profiling of the KRAS mutation status. Within this article we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
